Puma Biotechnology Reports Fourth Quarter and Full Year 2012 Financial Results

[at noodls] – During 2012, Puma made significant progress with the clinical development of our drug candidate PB272 in HER2-positive metastatic breast cancer, HER2-positive neoadjuvant breast cancer, HER2-mutated … more

View todays social media effects on PBYI

View the latest stocks trending across Twitter. Click to view dashboard

See who Puma is hiring next, click here to view